Viking Therapeutics Inc.

NASDAQ: VKTX · Real-Time Price · USD
40.04
-0.20 (-0.50%)
At close: Aug 15, 2025, 3:59 PM
40.55
1.27%
After-hours: Aug 15, 2025, 06:49 PM EDT

Viking Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a 292K 291K 296K
Gross Profit
n/a -292K -291K -296K
Operating Income
-150.92M -100.83M -70.36M -55.68M
Interest Income
n/a 15.02M 1.59M 703K
Pretax Income
-109.96M -85.89M -68.87M -54.99M
Net Income
-109.96M -85.89M -67.38M -54M
Selling & General & Admin
49.28M 37.02M 16.12M 10.7M
Research & Development
101.64M 63.81M 54.23M 44.98M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
150.92M 100.83M 70.36M 55.68M
Interest Expense
n/a 88K n/a 18K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
n/a 100.83M 70.36M 55.68M
Income Tax Expense
n/a n/a -1.49M -988K
Shares Outstanding (Basic)
109.04M 94.35M 76.83M 77.2M
Shares Outstanding (Diluted)
109.04M 94.35M 76.83M 77.2M
EPS (Basic)
-1.01 -0.91 -0.88 -0.7
EPS (Diluted)
-1.01 -0.91 -0.88 -0.7
EBITDA
-109.52M -100.83M -70.36M -55.39M
EBIT
-109.87M -100.83M -70.36M -55.68M
Depreciation & Amortization
n/a 292K 291K 296K